Actively Recruiting

Age: 18Years +
All Genders
NCT05737953

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Led by Zhaoshen Li · Updated on 2025-02-11

100

Participants Needed

1

Research Sites

126 weeks

Total Duration

On this page

Sponsors

Z

Zhaoshen Li

Lead Sponsor

O

Oriental Hepatobiliary Surgery Hospital Affiliated to Naval Military Medical University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. Participants will Provide post-operative cyst fluid specimens.

CONDITIONS

Official Title

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects are 60; 18 years old, regardless of gender
  • Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor
  • Subjects voluntarily accepted radical resection of pancreatic cystic tumors
  • Subjects or family members voluntarily sign the informed consent form for clinical research
Not Eligible

You will not qualify if you...

  • The excised sample does not contain cystic components, or the cystic fluid cannot be collected
  • Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation
  • Receive antibiotic treatment within 1 week before operation
  • Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor
  • The subjects or their families refused to sign the informed consent form for clinical research

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Changhai Hospital

Shanghai, Shanghai Municipality, China, 200433

Actively Recruiting

Loading map...

Research Team

K

Kaixuan Wang

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples | DecenTrialz